PSNL$8.57
$8.6542
Chart
Performance
Key Stats
AI PSNL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldPersonalis (PSNL) presents a mixed investment profile. While exhibiting strong performance over the past year and operating in a growing market, the company is not yet profitable and faces significant technical headwinds. Thematic alignment is moderate, but fundamental and technical factors warrant a cautious approach.
Thematic
Personalis operates within the personalized medicine and genomic testing sector, benefiting from the growing trend in targeted cancer therapies and diagnostics. Its focus on liquid biopsies and advanced analytics aligns with key advancements in healthcare.
Fundamental
Personalis has shown strong revenue growth in recent periods, but this has not yet translated into profitability. The company consistently reports net losses and negative EPS, and its current valuation metrics (P/S ratio) are high given the lack of profitability.
Technical
The stock is trading below key long-term moving averages and shows weak momentum across multiple timeframes. Recent performance indicates a significant downward trend, and technical indicators suggest further downside risk in the short to medium term.
| Factor | Score |
|---|---|
| Genomic Sequencing & Diagnostics | 75 |
| Personalized Medicine | 70 |
| Biotechnology & Healthcare Innovation | 60 |
| Regulatory Landscape (Healthcare) | 50 |
| Collaboration & Partnerships | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 15 |
| Growth | 70 |
| Balance Sheet Health | 75 |
| Cash Flow | 20 |
| Earnings Trend | 55 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 65 |
| Short-term Trends (1h, 4h) | 40 |
| Performance (1M) | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Long-Term Performance
The stock has demonstrated significant year-over-year growth, with a 1Y performance of 116.14% and a 6M performance of 11.79%, indicating robust investor returns over these periods.
Focus on Advanced Cancer Genomics
Personalis, Inc. specializes in advanced cancer genomic tests and services, including liquid biopsy tests (NeXT Personal, NeXT Personal Dx) for MRD and therapy monitoring, and tissue-based services (ImmunoID NeXT) for multi-dimensional tumor analysis. This focus aligns with the growing demand for personalized medicine in oncology.
Bearish Points (7)
Persistent Net Losses
Personalis has consistently reported net losses, with a TTM net income of -$71.264 million and a net margin of -96.1% in 2024. This sustained unprofitability poses a significant risk to long-term viability.
Stagnant Revenue and Decreasing Net Margin
While revenue increased from $65.047 million in 2022 to $84.614 million in 2024, the net margin has worsened from -174.2% in 2022 to -96.1% in 2024, indicating that revenue growth is not translating into profitability and operational efficiency may be declining.
Calendar
August 2025
6
Next Earnings Date
H: $-0.23
A: $-0.24
L: $-0.27
H: 20.50M
A: 20.12M
L: 19.90M
Profile
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Seasonals
Price Target
7.14 USD
The 39 analysts offering 1 year price forecasts for PSNL have a max estimate of 9.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in precision oncology, particularly liquid biopsy and comprehensive genomic profiling, overlapping with Personalis' focus on advanced cancer diagnostics.
Weight: 90
Leading developer of DNA sequencing technologies and instruments, a foundational technology provider to Personalis and a key player in the broader genomics ecosystem.
Weight: 88
Major player in cancer diagnostics, including molecular and genomic tests, often considered a direct competitor for market share in the oncology diagnostics space.
Weight: 87
Specializes in cell-free DNA testing with significant applications in oncology, including minimal residual disease (MRD) monitoring, directly aligning with PSNL's cancer genomics focus.